• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Epstein David R

    7/15/22 6:00:25 PM ET
    $DYNS
    Get the next $DYNS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Epstein David R

    (Last) (First) (Middle)
    C/O SENTI BIOSCIENCES, INC.
    2 CORPORATE DRIVE FIRST FLOOR

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Senti Biosciences, Inc. [ SNTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/13/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.75 07/13/2022 A 125,000 (1) 07/12/2032 Common Stock 125,000 $0.00 125,000 D
    Explanation of Responses:
    1. The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Mike Rhee, attorney-in-fact 07/15/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DYNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DYNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Knobelman Deborah was granted 30,000 shares

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    10/4/22 4:47:13 PM ET
    $DYNS

    SEC Form 4 filed by Rajangam Kanya

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/20/22 6:00:12 PM ET
    $DYNS

    SEC Form 4 filed by Mathers Edward T

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/15/22 6:09:58 PM ET
    $DYNS

    $DYNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits

    - Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the completion of its business combination with Dynamics Special Purpose Corp. (("D

    6/9/22 7:30:00 AM ET
    $DYNS

    Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environment

    1/6/22 8:02:00 AM ET
    $DYNS

    Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

    - Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity ("PIPE") financing and from non-redemption agreements -  - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds - - Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts man

    12/20/21 7:05:00 AM ET
    $DYNS
    $ILMN
    $MRNA
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Laboratory Analytical Instruments

    $DYNS
    SEC Filings

    View All

    Dynamics Special Purpose Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    1/9/23 7:54:29 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:23:31 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:20:56 AM ET
    $DYNS

    $DYNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Dynamics Special Purpose Corp.

    SC 13D - Senti Biosciences, Inc. (0001854270) (Subject)

    7/15/22 5:24:53 PM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    4/5/22 11:21:36 AM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    2/14/22 5:07:15 PM ET
    $DYNS